Nalbuphine en es it fr

Nalbuphine Brand names, Nalbuphine Analogs

Nalbuphine Brand Names Mixture

  • No information avaliable

Nalbuphine Chemical_Formula


Nalbuphine RX_link

Nalbuphine fda sheet

Nalbuphine msds (material safety sheet)

Nalbuphine MSDS

Nalbuphine Synthesis Reference

No information avaliable

Nalbuphine Molecular Weight

357.443 g/mol

Nalbuphine Melting Point

230 oC as HCl salt

Nalbuphine H2O Solubility

35.5 mg/mL at 25 oC as HCl salt

Nalbuphine State


Nalbuphine LogP


Nalbuphine Dosage Forms

Solution (suitable for subcutaneous, intramuscular, or intravenous injection - available as 10 mg or 20 mg of nalbuphine hydrochloride per mL)

Nalbuphine Indication

For the relief of moderate to severe pain.

Nalbuphine Pharmacology

Nalbuphine is a synthetic opioid agonist-antagonist analgesic of the phenanthrene series. Nalbuphine's analgesic potency is essentially equivalent to that of morphine on a milligram basis. The opioid antagonist activity of nalbuphine is one-fourth as potent as nalorphine and 10 times that of pentazocine. Nalbuphine by itself has potent opioid antagonist activity at doses equal to or lower than its analgesic dose. When administered following or concurrent with mu agonist opioid analgesics (e.g., morphine, oxymorphone, fentanyl), nalbuphine may partially reverse or block opioid-induced respiratory depression from the mu agonist analgesic. Nalbuphine may precipitate withdrawal in patients dependent on opioid drugs. Nalbuphine should be used with caution in patients who have been receiving mu opioid analgesics on a regular basis.

Nalbuphine Absorption

The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.

Nalbuphine side effects and Toxicity

ORAL (LD50): Acute: 1100 mg/kg [Dog]. Symptoms of overdose include primarily sleepiness and mild dysphoria.

Nalbuphine Patient Information

Nalbuphine Organisms Affected

Humans and other mammals